• Atossa Therapeutics entered a stapled contingent value rights (CVR) agreement on October 8, 2026.
• The dividend provides one CVR per common share outstanding as of October 19, 2026, or issued thereafter.
• CVRs remain attached to the underlying shares and cannot trade separately unless the board elects to detach them.
• Holders collectively receive 25% of net proceeds from monetizing the first qualifying FDA priority review voucher, capped at $50 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-454486), on November 10, 2026, and is solely responsible for the information contained therein.